| How many drug targets are there? JP Overington, B Al-Lazikani, AL Hopkins Nature Reviews Drug Discovery 5 (12), 993-996, 2006 | 4613 | 2006 |
| ChEMBL: a large-scale bioactivity database for drug discovery A Gaulton, LJ Bellis, AP Bento, J Chambers, M Davies, A Hersey, Y Light, ... Nucleic Acids Research 40, D1100-1107, 2012 | 4222 | 2012 |
| The ChEMBL database in 2017 A Gaulton, A Hersey, M Nowotka, AP Bento, J Chambers, D Mendez, ... Nucleic acids research 45 (D1), D945-D954, 2017 | 2312 | 2017 |
| A comprehensive map of molecular drug targets R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, ... Nature reviews Drug discovery 16 (1), 19-34, 2017 | 2210 | 2017 |
| The ChEMBL bioactivity database: an update AP Bento, A Gaulton, A Hersey, LJ Bellis, J Chambers, M Davies, ... Nucleic acids research 42 (D1), D1083-D1090, 2014 | 1656 | 2014 |
| An atlas of genetic influences on human blood metabolites SY Shin, EB Fauman, AK Petersen, J Krumsiek, R Santos, J Huang, ... Nature Genetics 46, 543-540, 2014 | 1394 | 2014 |
| The genome of the blood fluke Schistosoma mansoni M Berriman, BJ Haas, PT LoVerde, RA Wilson, GP Dillon, GC Cerqueira, ... Nature 460 (7253), 352-358, 2009 | 1214 | 2009 |
| The promise and peril of chemical probes CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ... Nature chemical biology 11 (8), 536-541, 2015 | 854 | 2015 |
| A community effort to assess and improve drug sensitivity prediction algorithms. WK Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, Bansal M ... Nat Biotechnol. 32 (6), 2014 | 786 | 2014 |
| HOMSTRAD: a database of protein structure alignments for homologous families K Mizuguchi, CM Deane, TL Blundell, JP Overington Protein Science 7 (11), 2469-2471, 1998 | 661 | 1998 |
| ChEMBL web services: streamlining access to drug discovery data and utilities M Davies, M Nowotka, G Papadatos, N Dedman, A Gaulton, F Atkinson, ... Nucleic acids research 43 (W1), W612-W620, 2015 | 634 | 2015 |
| X-ray analysis of HIV-1 proteinase at 2.7A resolution confirms structural homology among retroviral enzymes R Lapatto, T Blundell, A Hemmings, J Overington, A Wilderspin, S Wood, ... Nature 342 (6247), 299-302, 1989 | 625 | 1989 |
| Can we rationally design promiscuous drugs? AL Hopkins, JS Mason, JP Overington Current Opinion In Structural Biology 16 (1), 127-136, 2006 | 604 | 2006 |
| The druggable genome and support for target identification and validation in drug development C Finan, A Gaulton, FA Kruger, RT Lumbers, T Shah, J Engmann, ... Science translational medicine 9 (383), eaag1166, 2017 | 585 | 2017 |
| Probing the links between in vitro potency, ADMET and physicochemical parameters MP Gleeson, A Hersey, D Montanari, J Overington Nature reviews Drug discovery 10 (3), 197-208, 2011 | 538 | 2011 |
| JOY: protein sequence-structure representation and analysis. K Mizuguchi, CM Deane, TL Blundell, MS Johnson, JP Overington Bioinformatics 14 (7), 617-623, 1998 | 482 | 1998 |
| Environment‐specific amino acid substitution tables: Tertiary templates and prediction of protein folds J Overington, D Donnelly, MS Johnson, A Šali, TL Blundell Protein Science 1 (2), 216-226, 1992 | 400 | 1992 |
| A Structural Basis for Sequence Comparisons: An Evaluation of Scoring Methodologies MS Johnson, JP Overington Journal of Molecular Biology 233 (4), 716-738, 1993 | 396 | 1993 |
| Unexplored therapeutic opportunities in the human genome TI Oprea, CG Bologa, S Brunak, A Campbell, GN Gan, A Gaulton, ... Nature reviews Drug discovery 17 (5), 317-332, 2018 | 393 | 2018 |
| Derivation of rules for comparative protein modeling from a database of protein structure alignments A Šali, JP Overington Protein Science 3 (9), 1582-1596, 1994 | 393 | 1994 |
George PapadatosHead of Data, Syngenta CP R&DVerified email at syngenta.com
